Justin Hasenkamp
Overview
Explore the profile of Justin Hasenkamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shumilov E, Hasenkamp J, Maulhardt M, Mazzeo P, Schmidt N, Boyadzhiev H, et al.
Hematol Oncol
. 2022 Apr;
40(4):763-776.
PMID: 35368106
Second allogeneic stem cell transplantation (allo-SCT2) represents a rescue option for selected patients (pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML). Still, relapse rates post-allo-SCT2 remain high and effective anti-relapse...
12.
Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al.
Blood
. 2022 Mar;
140(4):349-358.
PMID: 35316325
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Here, we report the first German...
13.
Wurm-Kuczera R, Buentzel J, Koenig J, Legler T, Valk J, Hasenkamp J, et al.
Front Immunol
. 2021 Oct;
12:746996.
PMID: 34691055
Purpose: Extrinsic factors and genetic predisposition contribute to the etiology of sarcoidosis, converging in a phenotype of altered immune response associated with multisystemic inflammatory granulomatous tissue infiltration. Immunological reconstitution after...
14.
Boll B, Schalk E, Buchheidt D, Hasenkamp J, Kiehl M, Kiderlen T, et al.
Ann Hematol
. 2020 Sep;
100(1):239-259.
PMID: 32997191
Cancer patients frequently require central venous catheters for therapy and parenteral nutrition and are at high risk of central venous catheter-related infections (CRIs). Moreover, CRIs prolong hospitalization, cause an excess...
15.
Hasenkamp J, Riggert J, Jung W, Boyadzhiev H, Valk J, Trumper L, et al.
Ann Hematol
. 2020 Sep;
100(12):3041-3042.
PMID: 32885286
No abstract available.
16.
Schmalz G, Busjan R, Dietl M, Hasenkamp J, Trumper L, Ziebolz D
Oral Health Prev Dent
. 2020 Jun;
18(3):461-466.
PMID: 32515417
Purpose: Knowledge about oral health-related quality of life (OHRQoL) in adult patients with leukaemia is still limited. Accordingly, aim of this cross-sectional study was to assess OHRQoL and its associations...
17.
Mika T, Maghnouj A, Klein-Scory S, Ladigan-Badura S, Baraniskin A, Thomson J, et al.
Front Mol Biosci
. 2020 Jun;
7:84.
PMID: 32500079
CD19-directed CAR-T-cells (CD19-CAR) have demonstrated remarkable clinical results in patients suffering from refractory or relapsed lymphoma and acute lymphoblastic leukemia. In order to further optimize follow-up, to explain treatment failure,...
18.
Schmalz G, Tulani L, Busjan R, Haak R, Kottmann T, Trumper L, et al.
Adv Hematol
. 2020 May;
2020:6710906.
PMID: 32373173
This retrospective pilot study aimed to detect whether remaining dental/periodontal treatment need and periodontal inflammation after dental clearance would be associated with the initial therapy outcome of adult patients with...
19.
Shumilov E, Hasenkamp J, Szuszies C, Koch R, Wulf G
Acta Haematol
. 2020 Apr;
144(1):105-110.
PMID: 32259827
Initial treatment with the monoclonal anti-CD52 antibody alemtuzumab induces responses in the majority of patients with T-cell prolymphocytic leukemia (T-PLL). In eligible patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is...
20.
Ruhnke M, Cornely O, Schmidt-Hieber M, Alakel N, Boell B, Buchheidt D, et al.
Mycoses
. 2020 Apr;
63(7):653-682.
PMID: 32236989
Background: Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on...